Dondov, Ganchimeg

Товч нэр

Dondov, Ganchimeg

Бүтэн нэр

Dondov Ganchimeg

Латин нэр

Dondov Ganchimeg

Албан тушаал

Судлаач

Харьяалал

Анагаахын Шинжлэх Ухааны Үндэсний Их Сургууль

ORCID

0000-0001-6314-6996

Scopus Author ID

57572273500

Now showing 1 - 10 of 11

Some of the metrics are blocked by your
consent settings
Diagnostic accuracy of serum pepsinogens for detecting chronic atrophic gastritis and gastric cancer: A meta-analysis
(2026-07-07)
Ganchimeg Dondov
;
Bayarmaa Nyamaa
;
Batbold Batsaikhan
;
Tegshjargal Badamjav
;
Sodnomtsogt Lkhagvasuren
Introduction: Recent studies have shown that serological biomarkers such as pepsinogens may facilitate the early detection of gastric cancer. Objective: This study aims to evaluate the diagnostic performance of serum pepsinogen I (PGI) and the PGI/pepsinogen II ratio (PGR) in detecting gastric cancer and chronic atrophic gastritis. Methods: A systematic literature search was conducted using MeSH terms related to atrophic gastritis, gastric neoplasms, pepsinogen A, sensitivity, and specificity. Twenty-one eligible studies were included in the quantitative synthesis. Results: For atrophic gastritis, the area under the curve was 0.74 (95% confidence interval [CI] = 0.70–0.77) for PGI and 0.78 (95% CI = 0.75–0.82) for PGR. The pooled sensitivity and specificity were 61.4% (95% CI = 48.2–73.2) and 86.4% (95% CI = 61.8–96.1), respectively, for PGI, and 72.4% (95% CI = 61.0–81.4) and 76.9% (95% CI = 49.5–91.9), respectively, for PGR. For gastric cancer detection, the area under the curve values were 0.76 (95% CI = 0.72–0.80) for PGI, 0.77 (95% CI = 0.73–0.80) for PGR, and 0.79 (95% CI = 0.75–0.83) for the combined PGI+PGR model. The pooled sensitivity and specificity were 69.8% (95% CI = 55.0–81.3) and 70.8% (95% CI = 58.7–80.6), respectively, for PGI, 76.2% (95% CI = 65.4–84.2) and 66.1% (95% CI = 56.1–74.8), respectively, for PGR, and 61.5% (95% CI = 50.9–72.1) and 86.7% (95% CI = 79.4–94.1), respectively, for PGI+PGR. Conclusion: Serum PGI and PGR can be used as an additional screening for high-risk subjects who may require gastroscopy or biopsy.
Some of the metrics are blocked by your
consent settings
Topical Meconium Improves Barrier Repair and Reduces Skin Inflammation in a Rat Model of Eczema
(2025-12-15)
Anudari Ichinkhorloo
;
Khuslen Batzorig
;
Ganchimeg Dondov
;
Batbold Batsaikhan
;
Tsend-Ayush Damba
Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by epidermal barrier dysfunction and immune dysregulation. While traditionally considered a waste product, meconium—the first stool of neonates—contains various bioactive compounds that may influence immune responses and epithelial integrity. This study investigates the dermatological effects of meconium in a chemically induced eczema model in Wistar rats, focusing on its potential to modulate inflammation and promote skin barrier repair. Meconium samples were collected from healthy neonates and applied topically to rats with Veet-induced eczema. The experimental groups included untreated eczema controls, meconium-treated rats, Meebo ointment-treated rats (positive control), and a healthy control group. Clinical assessments of erythema, ulceration, and edema were conducted, alongside histopathological evaluations of epidermal thickness and immune cell infiltration. Statistical analyses were performed using ANOVA with post-hoc Tukey tests. Meconium treatment significantly reduced erythema and ulceration scores compared to untreated eczema controls (p<0.01) and increased epidermal thickness (p<0.05). While less effective than Meebo ointment, meconium demonstrated notable anti-inflammatory and regenerative properties. The findings suggest that meconium contains bioactive components capable of modulating skin inflammation and enhancing barrier repair, warranting further investigation into its potential therapeutic applications in dermatological conditions.
Some of the metrics are blocked by your
consent settings
Topical Meconium Improves Barrier Repair and Reduces Skin Inflammation in a Rat Model of Eczema
(2025-12-30)
Anudari Ichinkhorloo
;
Khuslen Batzorig
;
Ganchimeg Dondov
;
Batbold Batsaikhan
;
Tsend-Ayush Damba
Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by epidermal barrier dysfunction and immune dysregulation. While traditionally considered a waste product, meconium—the first stool of neonates—contains various bioactive compounds that may influence immune responses and epithelial integrity. This study investigates the dermatological effects of meconium in a chemically induced eczema model in Wistar rats, focusing on its potential to modulate inflammation and promote skin barrier repair. Meconium samples were collected from healthy neonates and applied topically to rats with Veet-induced eczema. The experimental groups included untreated eczema controls, meconium-treated rats, Meebo ointment-treated rats (positive control), and a healthy control group. Clinical assessments of erythema, ulceration, and edema were conducted, alongside histopathological evaluations of epidermal thickness and immune cell infiltration. Statistical analyses were performed using ANOVA with post-hoc Tukey tests. Meconium treatment significantly reduced erythema and ulceration scores compared to untreated eczema controls (p<0.01) and increased epidermal thickness (p<0.05). While less effective than Meebo ointment, meconium demonstrated notable anti-inflammatory and regenerative properties. The findings suggest that meconium contains bioactive components capable of modulating skin inflammation and enhancing barrier repair, warranting further investigation into its potential therapeutic applications in dermatological conditions.
Some of the metrics are blocked by your
consent settings
Topical Meconium Improves Barrier Repair and Reduces Skin Inflammation in a Rat Model of Eczema
(2025-12-15)
Anudari Ichinkhorloo
;
Khuslen Batzorig
;
Ganchimeg Dondov
;
Batbold Batsaikhan
;
Tsend-Ayush Damba
Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by epidermal barrier dysfunction and immune dysregulation. While traditionally considered a waste product, meconium—the first stool of neonates—contains various bioactive compounds that may influence immune responses and epithelial integrity. This study investigates the dermatological effects of meconium in a chemically induced eczema model in Wistar rats, focusing on its potential to modulate inflammation and promote skin barrier repair. Meconium samples were collected from healthy neonates and applied topically to rats with Veet-induced eczema. The experimental groups included untreated eczema controls, meconium-treated rats, Meebo ointment-treated rats (positive control), and a healthy control group. Clinical assessments of erythema, ulceration, and edema were conducted, alongside histopathological evaluations of epidermal thickness and immune cell infiltration. Statistical analyses were performed using ANOVA with post-hoc Tukey tests. Meconium treatment significantly reduced erythema and ulceration scores compared to untreated eczema controls (p<0.01) and increased epidermal thickness (p<0.05). While less effective than Meebo ointment, meconium demonstrated notable anti-inflammatory and regenerative properties. The findings suggest that meconium contains bioactive components capable of modulating skin inflammation and enhancing barrier repair, warranting further investigation into its potential therapeutic applications in dermatological conditions.
Some of the metrics are blocked by your
consent settings
Risk Assessment of Gastric Cancer and Precancerous Condition Using Serum Pepsinogen and H. Pylori Antibody Test
(Mongolian National University of Medical Sciences, 2023-03-30)
Ganchimeg Dondov
;
Bayarmaa Nyamaa
;
Tegshjargal Badamjav
;
Batbold Batsaikhan
;
Erkhembulgan Purevdorj
Objectives: We aimed to determine serum PGs (serum pepsinogens) and H. Pylori IgG in atrophic gastritis and gastric cancer patients and evaluate the gastric cancer risk.Method: We enrolled 40 gastric cancer patients, 40 chronic atrophic gastritis patients and 40 healthy control subjects. Serum PGI, PGII, and H. pylori IgG levels were measured by ELISA. The PGI to PGII ratio was calculated.Results: The mean age of the subjects was 60±10.9 years, We found that 52.6% (n=60) were male. H. Pylori IgG was positive in 67 subjects. The serum PGI and PGR levels were significantly decreased in gastric cancer and atrophic gastritis groups compared to the healthy control. According to classification ABC (D), group D had higher proportion of atrophic gastritis cases, group C had higher proportion of gastric cancer cases than others. Additionally, we evaluated all subjects by giving one point to each of the age ≤40, positive family history of gastric cancer, positive previous gastric disease history, PGI ≤75.07 ng/ml, PGR ≤6.25, or two point to each of PGI ≤35.25 ng/ml, and PGR ≤5.27, with score ranging between 0-7. As score increased, the risk of atrophic gastritis or gastric cancer increased.Conclusion: A combination of methods involving PGs and other risk factors may predict the probability of gastric cancer and could identify individuals who may need upper endoscopy.
Some of the metrics are blocked by your
consent settings
The Dynamics of the Prevalence of Acute Viral Hepatitis and the Strategies against Viral Hepatitis in Mongolia
(2024)
Badamnachin, Batsukh
;
Badamjav, Tegshjargal
;
Dondov, Ganchimeg
;
Dashjamts, Gantogtokh
;
Tserendorj, Chinbayar
BACKGROUND: Hepatocellular carcinoma (HCC) is the most common cancer in Mongolia. The relative importance of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in HCC etiology is known to vary greatly from one part of the world to another. Principally, 95% of HCC patients have chronic viral hepatitis, including 53% hepatitis B virus, 38.9% HCV, and 5.6% have HBV/HCV coinfection. Hepatitis D virus (HDV) infection is widely spread in our country, anti-HDV has been found in more than 25% of carriers who have HBsAg. MATERIALS AND METHODS: We analyzed data of patients who had been diagnosed with acute viral hepatitis in the Department of adult hepatitis, National Center for Communicable Diseases in Mongolia from 1952 to 2018. RESULTS: A total of 318,831 cases of acute viral hepatitis were registered in Mongolia between 1981 and 2019, which is 34.9 cases per 10,000 population. Of these, 265,931 cases of acute viral hepatitis A, or 28.6 per 10,000 populations, 48,855 cases of acute viral hepatitis B, or 5.5 cases per 10,000 populations, and 2,607 cases of acute viral hepatitis C, or 0.4 cases per 10,000 populations were recorded. CONCLUSION: The prevalence of viral hepatitis in our country was the highest in 1981-1991, but since 2012, the prevalence of infection has steadily decreased. In Mongolia, since 1960, multifaceted programs and activities to combat viral hepatitis have been successfully implemented at the national level. HOW TO CITE THIS ARTICLE: Badamnachin B, Badamjav T, Dondov G, et al. The Dynamics of the Prevalence of Acute Viral Hepatitis and the Strategies against Viral Hepatitis in Mongolia. Euroasian J Hepato-Gastroenterol 2024;14(1):65-69.
Some of the metrics are blocked by your
consent settings
Genetic Risk of MASLD in Mongolians: Role of PNPLA3 and FTO SNPs
(2025-08)
Tsedendorj, Yumchinsuren
;
Daramjav, Dolgion
;
Enkhbat, Yesukhei
;
Dondov, Ganchimeg
;
Dashjamts, Gantogtokh
BACKGROUND: This study aimed to determine the association between PNPLA3 rs738409, rs2896019, and FTO rs9939609, rs17817449 single-nucleotide polymorphisms and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in Mongolian individuals. METHODS: We conducted a case-control study, enrolling 100 MASLD patients and 50 subjects without MASLD. We used the PCR-RFLP technique on three genotype SNPs (rs738409, rs2896019 in PNPLA3, and rs9939609 in FTO). We analyzed liver function and lipid metabolism parameters in the peripheral blood of study participants. A p-value below 0.05 was considered a statistically significant result. RESULTS: This study, which included 150 participants aged 23 to 75, had a mean age of 46.73 ± 11.45 years, with 40% of participants being male (60 individuals). We observed the rs738409 (G), rs2896019 (G), and rs9939609 (A) alleles at a statistically significantly enhanced frequency in the case group (32.5%, 33%, and 21%) compared to the control group (19%, 25%, and 19%), indicating an increased risk of MASLD. The FTO rs17817449 SNP did not show a significant difference between groups. PNPLA3 rs738409 GC/GG genotype (OR = 2.39, p = 0.019) and FTO rs9939609 AT/AA (OR = 2.55, p = 0.025) genotype showed a significant association with MASLD. In the evaluation of the FTO rs9939609, rs17817449, and PNPLA3 rs738409, rs2896019 single-nucleotide polymorphisms among the research individuals, 18.7% had no SNPs, 15.3% had one SNP, 29.3% had two SNPs, 25.3% had three SNPs, and 11.3% had four SNPs. The risk of MASLD increased significantly for individuals having four SNPs (OR = 4.23, p = 0.007). CONCLUSIONS: We found that PNPLA3 rs738409 GC/GG genotype and FTO rs9939609 AT/AA genotype are strongly associated with an increased risk of MASLD. Notably, individuals with a higher rate of SNP number, had a significantly higher risk of MASLD.
Scopus© Citations 6
Some of the metrics are blocked by your
consent settings
Post-Treatment Occurrence of Serum Cryoglobulinemia in Chronic Hepatitis C Patients.
(2024-06)
Dashjamts, Gantogtokh
;
Ganzorig, Amin-Erdene
;
Tsedendorj, Yumchinsuren
;
Dondov, Ganchimeg
;
Nergui, Otgongerel
Scopus© Citations 3
Some of the metrics are blocked by your
consent settings
Change in Estimated Glomerular Filtration Rate After Direct-Acting Antiviral Treatment in Chronic Hepatitis C Patients.
(2025-01)
Dashjamts, Gantogtokh
;
Ganzorig, Amin-Erdene
;
Tsedendorj, Yumchinsuren
;
Daramjav, Dolgion
;
Khayankhyarvaa, Enkhmend
Scopus© Citations 1
Some of the metrics are blocked by your
consent settings
Incidence and Mortality due to Colorectal Cancer in Mongolia, 2018-2022.
(2024-07)
Tsedendorj, Yumchinsuren
;
Zorigtbaatar, Sonor
;
Davaasuren, Nomin-Erdene
;
Dondov, Ganchimeg
;
Ganbat, Tsenguun
Scopus© Citations 3

Dondov, Ganchimeg

Filters

Settings

Sort By

Results per page